Company: REVB
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034584
Chunk: 32

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 16
Chunk 32
---
212

    —

    57,589

    —

    57,589

    Common stock issued for services

    —

    —

    653

    1

    24,999

    —

    25,000

    Class D Common Stock Warrants exercises

    —

    —

    6,312

    6

    241,384

    —

    241,390

    Class D Warrant Inducement exercises

    —

    —

    159,249

    159

    3,501,117

    —

    3,501,276

    Class E Common Stock Warrant Inducement exercises

    —

    —

    254,002

    254

    3,687,664

    —

    3,687,918

    Stock-based compensation expense

    —

    —

    —

    —

    168,850

    —

    168,850

    Net loss

    —

    —

    —

    —

    —

    (15,038,536
    )

    (15,038,536
    )

    Balance as of December 31, 2024

    —

    $
    —

    522,223

    $
    522

    $
    45,213,498

    $
    (40,505,638
    )
     
    $
    4,708,382

See accompanying notes to the consolidated financial statements.

 F-6

REVELATION BIOSCIENCES, INC. 

Consolidated Statements of Cash Flows

    Year EndedDecember 31,

    2024

    2023

    Cash flows from operating activities:

    Net loss
     
    $
    (15,038,536
    )

    (120,254
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Stock-based compensation expense

    168,850

    155,721

    Issuance of common stock for services

    25,000

    —

    Depreciation expense

    27,923

    25,049

    Change in fair value of warrant liability

    (81,441
    )

    (8,328,937
    )

    Changes in operating assets and liabilities:

    Prepaid expenses and other current assets

    17,992

    (11,559
    )

    Deferred